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Does the presence of regional lymph node metastases have
any impact on the complete remission rate in patients with
distant metastases of papillary thyroid carcinoma (PTC),
treated by radioiodine therapy?
Czy obecność przerzutów odległych i/lub do węzłów chłonnych ma wpływ
na częstość uzyskania pełnej remisji u chorych z rakiem brodawkowatym
tarczycy (PTC) leczonych radiojodem?
Tomasz Trybek, Aldona Kowalska
Department of Endocrinology and Nuclear Medicine, Hollycross Cancer Centre, Kielce
Abstract
Introduction: The presence of regional nodal and/or distant metastases has an influence on the results of treatment in patients with
differentiated thyroid carcinoma (DTC).
The aim of the study was to evaluate the frequency of complete remission in patients with DTC depending on the presence of lymph
nodes and/or distant metastases.
Material and methods: A total of 102 patients (82 females, 20 males) aged 20–86 with N1 or M1 (according to TNM staging) after thyroidec-
tomy and 131I therapy were chosen from among the 625 patients with DTC who were treated in our Department. The patients were divided
in 3 groups: group I — TxN1M0, group II — TxN0M1, and group III — TxN1M1.
The documentation was analyzed by classifying the complete remission patients as being those without the presence of radioiodine
uptake in the neck or pathological lesions in the whole body 131I scintigraphy scan after six months of ablation therapy, with negative
serum thyroglobulin in the absence of anti-thyroglobulin antibodies, and with normal ultrasound image of the neck. We compared the
frequency of complete remission in three groups of patients.
Results: We recognized complete remission in 57 patients (82.6%) in group I (TxN1M0), 4 patients (28.6%) in group II (TxN0M1) and
6 patients (31.6%) in group III (TxN1M1).
Conclusions:
1. The highest percentage of complete remission was observed in patients with lymph nodes but without distant metastases (group I).
2. In the case of the presence of distant metastases there was no statistically significant difference in the percentage of complete remission
between patients with or without the presence of metastases in lymph nodes.
(Pol J Endocrinol 2010; 61 (5): 443–445)
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Streszczenie
Wstęp: Obecność regionalnych i/lub odległych przerzutów ma wpływ na wyniki leczenia u pacjentów ze zróżnicowanym rakiem tarczycy.
Celem pracy była ocena częstości uzyskania pełnej remisji choroby u pacjentów z rakiem brodawkowatym tarczycy (DTC, differentiated
thyroid carcinoma) w zależności od obecności przerzutów w węzłach chłonnych i/lub przerzutów odległych.
Materiał i metody: Spośród 625 chorych na DTC leczonych w Świętokrzyskim Centrum Onkologii badaniem objęto 102 chorych (82
kobiety, 20 mężczyzn) w wieku 20–86 lat, z cechą N1 lub M1 według klasyfikacji TNM, postawionej po leczeniu operacyjnym i uzupełnia-
jącej terapii 131I. Chorych podzielono na trzy grupy: grupa I — T1-4N1M0 (69 chorych), grupa II — T1-4N0M1 (14 chorych), grupa III — T1-
-4N1M1 (19 chorych).
Poddano analizie dokumentację chorych, klasyfikując do pełnej remisji chorych, u których w badaniu diagnostycznym po 6 miesiącach
od leczenia uzupełniającego 131I nie stwierdzono jodochwytności w badaniu scyntygraficznym szyi i całego ciała, stężenie tyreoglobuliny
było nieoznaczalne przy braku przeciwciał anty-Tg, obraz USG szyi był prawidłowy. Porównano częstość remisji w trzech grupach.
Zastosowano dokładny test Fisher’a.
Wyniki: Pełną remisję uzyskało 57 chorych (82,6%) w grupie I (T1-4N1M0), 4 chorych (28,6%) w grupie II (T1-4N0M1), 6 chorych (31,6%)
w grupie III (T1-4N1M1). Stwierdzono znamienne statystycznie zróżnicowanie między grupą I i II (p = 0,0001) oraz grupą I i III (p < 0,0001).
Natomiast nie stwierdzono takiego zróżnicowania między grupą II i III (p = 1,0000).
Wnioski:
1. Największy odsetek pełnych remisji stwierdzono u chorych z zajęciem węzłów chłonnych, lecz bez przerzutów odległych (grupa I).
2. W przypadku obecności przerzutów odległych nie było istotnej statystycznie różnicy w odsetku pełnych remisji między chorymi
z obecnością lub bez przerzutów w węzłach chłonnych (grupa II v. III, p = 1,0000).
(Endokrynol Pol 2010; 61 (5): 443–445)
Słowa kluczowe: rak brodawkowaty tarczycy, przerzuty, pełna remisja
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Differentiated thyroid carcinomas (DTC) are usually
characterized by a good prognosis and survival of pa-
tients [1–5]. Papillary thyroid carcinoma (PTC) repre-
sents 75–80% DTC, and 10-year survival is observed in
98% of patients. However, the disease may have an
aggressive course and 5–27% of patients with DTC de-
velop regional and/or distant metastases. Prognostic
factors for recurrences include age, male gender, large
tumour size, local tumour invasion, lymph node and
distant metastases, poorly differentiated histological
type, thyroidectomy, and the absence of ablative treat-
ment with radioiodine [1, 6–11]. The significance of
lymph nodes for prognosis of PTC has been a matter of
controversy for a long period of time and report
emerged on a higher probability of remission and sur-
vival in patients with DTC in the N0M1 group com-
pared to those in the N1M1 group, according to the
TNM classification [12].
The aim of the study was to evaluate the frequency
of complete remission in patients with PTC, depend-
ing on the presence of lymph node metastases accom-
panying distant metastases.
Material and methods
A total of 102 patients (82 females, 20 males) aged 20-86
with N1 or M1 (according to the TNM classification)
after total thyroidectomy and 131I therapy were select-
ed from 625 patients with PTC treated in our Depart-
ment. The patients were divided in 3 groups: group I
— T1-4N1M0 (69 patients), group II — T1-4N0M1
(14 patients), and group III — T1-4N1M1 (19 patients).
The documentation was analyzed retrospectively.
Complete remission was diagnosed if patients did not
show any presence of radioiodine uptake in the neck
or pathological lesions in the whole body by 131I scintig-
raphy scan done after six months of 131I therapy, had
negative serum thyroglobulin in the absence of anti-
thyroglobulin antibodies, and the ultrasound image of
the neck did not show recurrence. We compared the
frequency of complete remission in three groups of pa-
tients. The exact Fisher test was performed.
Results
We diagnosed complete remission in 57 patients (82.6%)
in group I (T1-4N1M0), 4 patients (28.6%) in group II
(T1-4N0M1), and 6 patients (31.6%) in group III (T1-
-4N1M1) (Fig. 1). The significant difference was found
between groups I and II (p = 0.0001) and between
groups I and III (p < 0.0001), while the remission rate
was similar in both groups M1, independently of the
presence or absence of lymph node metastases.
Discussion
Metastases to regional lymph nodes in papillary thy-
roid carcinoma are frequent, ranging from 35% to 70%
in different series and less than 20% in follicular carci-
noma. In particular, large, multiple, bilateral lymph
node metastases are negative prognostic factors associ-
ated with poor survival [7–11]. The 10-year survival rate
of DTC with regional lymph node metastases is esti-
mated at around 62%. Also, distant metastases occur
more frequently in these patients. Distant metastases
occur in approximately 10% of patients with DTC.
In the literature, complete remission after 131I treat-
ment of patients with distant radioiodine-avid me-
tastases is observed in 50% of patients with lung me-
tastases, in 9% of patients with bone metastases, and
in 7% of patients with lung and bone metastases. Ten-
year survival is estimated at 61% for lung metastases,
21% for bone metastases, and 13% for metastases to
both organs [13].
Figure 1. The percentage of complete remission of the disease in the studied groups of patients
Rycina 1. Częstość uzyskania pełnej remisji choroby w badanych grupach pacjentów
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Last year a report appeared to indicate a better prog-
nosis and longer survival in patients with DTC with
distant metastases, which was not accompanied by
metastasis to regional lymph nodes [12]. This observa-
tion prompted us to compare the rate of complete re-
mission observed after radioiodine therapy performed
after surgery, in relation to the presence of lymph node
or distant metastases. Although it is believed that lymph
node metastases are nearly always present if distant
metastases are diagnosed, we observed 14% of patients
with N0M1 DTC. They constituted 14/33 (42%) of all
patients with functional distant metastases. However,
there was no difference observed in remission rates
between patients with and without lymph node me-
tastases if distant metastases were simultaneously
present – in both groups only about a quarter of the
patients attained complete remission. In the absence of
distant metastases, patients with DTC-derived lymph
node metastases were cured in about three-quarters of
cases after surgery and radioiodine therapy.
Conclusions
The highest percentage of complete remission was ob-
served in patients with lymph nodes but without dis-
tant metastases. In case of presence of distant metastases
there was not statistically significant difference in the
percentage of complete remission between patients with
or without the presence of metastases in lymph nodes.
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